For example, olutasidenib is currently in clinical trials in combination with nivolumab for advanced solid tumors and glioma (57), but published literature on use of an IDH inhibitor with immunotherapy used a nonclinical tool inhibitor, which showed limited efficacy (56). This evidence concerns the gene IDH1 and glioma.